Contact
searchSearch
HMP Global
Login

Kidney Cancer

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
From Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
From Oncology
News
FDA Approves Belzutifan For Advanced Kidney Cancer
03/04/2024

Emry Lloyd

Emry Lloyd
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan,...
03/04/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
News
Interactive Data Visualization Tool Facilitates Shared Decision-Making in Kidney Cancer
09/21/2021
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an...
09/21/2021
Journal of Clinical Pathways
Quiz
Quiz: Disparities in Treatment Decision-Making for Kidney Cancer
09/02/2021
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are...
09/02/2021
Journal of Clinical Pathways
News
Clinical and Economic Impact of Early vs Delayed Progression After First-Line TKIs in Patients With Metastatic RCC
08/30/2021
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after...
08/30/2021
Journal of Clinical Pathways
News
Disparities in Treatment Decision-Making for Patients With Kidney Cancer
08/11/2021
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex,...
08/11/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways

Expert Insights

Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
Videos
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
04/21/2021
04/21/2021
Journal of Clinical Pathways
Videos
Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Videos
Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC
03/18/2021
03/18/2021
Journal of Clinical Pathways
Videos
Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC
02/25/2021
02/25/2021
Journal of Clinical Pathways
Metastatic Prostate Cancer
Interview
Closing the Gap in HRR Testing for Metastatic Prostate Cancer in Community Oncology
06/04/2026
Helen Latimer, MPH
Helen Latimer, MPH, discusses new real-world evidence showing increased homologous recombination repair (HRR) genetic testing among patients with metastatic prostate cancer and the potential of electronic health record (HER)-driven clinical...
Helen Latimer, MPH, discusses new real-world evidence showing increased homologous recombination repair (HRR) genetic testing among patients with metastatic prostate cancer and the potential of electronic health record (HER)-driven clinical...
Helen Latimer, MPH, discusses...
06/04/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part II
05/26/2026
Mark A. Socinski, MD
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part I
05/21/2026
Mark A. Socinski, MD
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this...
05/21/2026
Journal of Clinical Pathways
Olivia Lynch
Interview
Where Access Breaks Down: Uncovering Persistent Disparities in Early-Stage Lung Cancer Treatment
04/21/2026
Olivia Lynch, MD, MPH
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research findings about persistent racial disparities in access to curative treatment for early-stage lung cancer, pointing to systemic barriers that arise before patients ever reach the operating room.
A guest expert shares research...
04/21/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways

Newsfeed

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
News
Cabozantinib Dose Reductions May Indicate Adequate Dose Exposure Among Patients With Metastatic Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.
According to a retrospective...
03/11/2024
Oncology
News
FDA Approves Belzutifan For Advanced Kidney Cancer
03/04/2024

Emry Lloyd

Emry Lloyd
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan, an HIF-2α inhibitor, for the treatment of advanced kidney cancer, based on promising results from the phase 3 LITESPARK-005 trial led by Dana-Farber researchers.
The FDA has approved belzutifan,...
03/04/2024
Journal of Clinical Pathways
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
News
Interactive Data Visualization Tool Facilitates Shared Decision-Making in Kidney Cancer
09/21/2021
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an interactive visualization tool for kidney cancer with the potential to facilitate shared decision-making between patients and providers.
Researchers developed an...
09/21/2021
Journal of Clinical Pathways
News
Clinical and Economic Impact of Early vs Delayed Progression After First-Line TKIs in Patients With Metastatic RCC
08/30/2021
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after first-line TKIs for metastatic RCC is associated with worse outcomes and higher healthcare resource utilization and costs than delayed progression.
Early progression after...
08/30/2021
Journal of Clinical Pathways
News
Disparities in Treatment Decision-Making for Patients With Kidney Cancer
08/11/2021
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.
Study findings suggest that sex,...
08/11/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
10/08/2020
10/08/2020
Journal of Clinical Pathways
News
Geographic Distribution Creates Disparities in Access to MM CAR T Care Centers
06/03/2026
Rebecca Amrick
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of...
06/03/2026
Journal of Clinical Pathways
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways
News
Evolving Treatment Patterns in HCC Reflect Expanding Role of Immunotherapy
05/27/2026
Rebecca Amrick
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving...
05/27/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Guideline-Based Pathways Could Streamline Prior Authorization Processes
05/21/2026
Rebecca Amrick
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have...
05/21/2026
Journal of Clinical Pathways
News
Higher Radon Levels Connected to Increased Risk of Ovarian Cancer in Postmenopausal Women
05/21/2026
Rebecca Amrick
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds...
05/21/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
High-Risk Individuals Delay Lung Cancer Screenings Until Eligible Despite Expanded Medicare Access
05/18/2026
Rebecca Amrick
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s...
05/18/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
HCC Incidence Higher in Rural Populations Due to Changing Risk Factors and Access Barriers
05/15/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC)...
05/15/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Disparities in Treatment Decision-Making for Kidney Cancer
09/02/2021
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are increased rates of non-guideline-based treatment among women and Black and Hispanic patients with kidney cancer.
True or False: There are...
09/02/2021
Journal of Clinical Pathways
Quiz
Quiz: Oral Anticancer Agent Use for Metastatic RCC
05/05/2021
05/05/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use